社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
再生元制药公司(REGN)
盘后
775.00
1.06
+0.14%
17:43 EST
773.94
-6.56
-0.84%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
瞪羚侃新股
·
11-03
Biotech和大药企全新合作方式，诞生
谁说Biotech让大药企掏钱必须卖自家管线？一种很新的Biotech和大药企之间的交易合作方式已经出现。 10月30日，药明巨诺与再生元Regeneron签署战略合作补充协议：再生元为药明巨诺的MAGE-A4靶点产品相关特定开发活动提供资金，再生元获得药明巨诺自研的药品生产工艺的全球非独家许可，并获得药明巨诺自研的慢病毒载体制造工艺的选择权，药明巨诺将获得最高可达5000万美金的付款，涵盖首付款、产品开发里程碑付款、药品生产流程监管里程碑付款等一系列款项。 值得注意的是，此次涉及的MAGE-A4靶点产品（JWTCR001）是一款TCR-T疗法，由药明巨诺2022年下半年从2seventy bio（后续被再生元收购）引进，此次合作药明巨诺仍保留了大中华区开发及商业化该产品的权益，它并非是一次管线回收的交易。 尽管JWTCR001是引进的管线，但过往中国Biotech的交易历史来看，从未有过在同一个资产下引进方技术反哺授权方并获得技术授权付款的先河，药明巨诺和再生元这一创新式合作补充显然有很多价值挖掘点。 01 创新交易先河 从国内Biotech过往合作交易历史上，与海外药企达成合作无非几种，包括买卖管线权益、技术平台使用授权、药物特许权折现。 药明巨诺与再生元的合作并不完全属于上述任何一种，该合作款项由“产品开发款项+技术授权费用+选择权费用”组成，一是“再生元为药明巨诺特定开发活动提供资金”和存在产品里程碑开发付款，这更像是一种再生元资助和推动药明巨诺在国内开发这款引进管线，毕竟从药明巨诺自身的管线优先级来说这款管线并不算靠前；二是药明巨诺将自研的生产工艺非独家授权给再生元以及再加一个慢病毒载体制造工艺的技术授权选择权，过往国内Biotech大多数技术授权集中在新型分子发现的技术平台使用权，而这种药品和载体生产工艺授权是CGT Biotech独有的，在过往的交易合作中并不
Biotech和大药企全新合作方式，诞生
# 【复盘】静候最强11月！大家10月投资如何？
回复
评论
点赞
1
编组 21备份 2
分享
举报
寂寞一根烟.
·
10-04
$再生元制药公司(REGN)$
这么垃圾的么，就你跳水最凶
$再生元制药公司(REGN)$ 这么垃圾的么，就你跳水最凶
回复
评论
点赞
1
编组 21备份 2
分享
举报
Pan the man
·
10-02
药价政策新格局下的投资机会：为什么REGN值得关注？ 近期，美国医药政策迎来重大变化。特朗普政府宣布对进口药品征收高额关税，并要求药企在美国市场实施“最惠国定价”。辉瑞（Pfizer, PFE）率先达成协议，以降价换取三年关税豁免，并通过新平台“TrumpRx”直销药品。这一政策转变意味着：未来药企必须在美国市场面对更严格的价格管控，但能与政府达成协议的公司有望获得先发优势。 在这一背景下，生物制药龙头
$再生元制药公司(REGN)$
值得重点关注。 为什么选择REGN？ 1. 核心产品竞争力强 REGN的明星产品 Eylea（眼科药物） 在全球市场占据领先地位，即使在降价压力下，凭借其高临床价值和医生依赖度，需求仍具粘性。未来，Eylea高清剂量版（HD）有望进一步稳固市场地位。 2. 抗体研发平台优势 REGN长期深耕单克隆抗体技术，在免疫学和肿瘤学管线中积累大量潜在“爆款”药物。与政府谈判时，拥有多管线研发优势的公司，往往更容易通过差异化药物议价。 3. 与政府合作潜力 辉瑞的案例表明，率先与政府达成协议的药企能获得显著的市场回报。REGN在新冠疫情期间曾与政府深度合作研发抗体疗法，未来若进入TrumpRx平台，其与医保体系的绑定可能带来新的稳定现金流。 4. 财务稳健 REGN现金流强劲，资产负债率低，即使面临药价下调压力，也能保持研发投入，抵御行业波动。 相关概念股推荐 在特朗普新政和药品降价趋势下，以下几只股票同样具备布局价值： •
$安进(AMGN)$
作为美国老牌生物制药巨头，Amgen产品组合涵盖肿瘤、自身免疫及罕见病领域，产品线广泛。其长期分红与稳定增长属性，使其在
药价政策新格局下的投资机会：为什么REGN值得关注？ 近期，美国医药政策迎来重大变化。特朗普政府宣布对进口药品征收高额关税，并要求药企在美国市场实施“最惠...
回复
评论
点赞
1
编组 21备份 2
分享
举报
话题虎
·
08-15
【晒单有奖】终于跟上了巴菲特的步伐！快来晒晒你的UNH~
喜欢抄底的小虎们，大家有福了呀[可爱]一个芯片
$英特尔(INTC)$
，一个医疗
$礼来(LLY)$
，一个保险
$联合健康(UNH)$
，都涨得不错，这段时间大科技把其他板块流动性都抽干了，是该拣点便宜货了[得意]而且这一次，是有各个大佬的助阵的。最新13F数据，截止2025年 Q2，“大空头”Michael Burry本轮重点押注医疗板块，eg. 建仓了UNH、
$再生元制药公司(REGN)$
的长期看涨期权（Leap Call）和正股，合计超37%的仓位，对这个赛道接下来近一年都很乐观；David Tepper也在Q2加仓了7亿美元的UNH，减仓了拼多多、阿里巴巴等Q1重仓的中概；另外能把UNH股价盘后拉升10%的，主要还是巴菲特，他真的买了！伯克希尔·哈撒韦Q2买了15亿美元，超500万股的UNH，季末市值约16亿美元，另外加仓了
$纽柯钢铁(NUE)$
,
$莱纳建筑公司(LEN)$
,
$Pool Corporation(POOL)$
,
$霍顿房屋(DHI)$
，继续减持
【晒单有奖】终于跟上了巴菲特的步伐！快来晒晒你的UNH~
# UNH绩后冲高回落！接下来看涨or看跌？
精彩
vision:
$联合健康(UNH)$申请出战
回复
7
点赞
4
编组 21备份 2
分享
举报
27RR
·
08-01
$REGN(REGN)$
各位系好安全带，明早盘前将发布财报
$REGN(REGN)$ 各位系好安全带，明早盘前将发布财报
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
去会所
·
07-02
$再生元制药公司(REGN)$
还有两天，能涨30%？救救我的期权[流泪]
$再生元制药公司(REGN)$ 还有两天，能涨30%？救救我的期权[流泪]
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
再生元制药公司
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.regeneron.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。
11-20
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
11-07
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
10-29
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
10-28
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-28
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
10-06
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
08-01
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08-01
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
06-18
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
04-29
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04-29
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
04-04
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
02-05
年度报告
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
02-04
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-13
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
分时
5日
日
周
月
数据加载中...
最高
777.77
今开
776.30
量比
0.69
最低
770.30
昨收
780.50
换手率
0.37%
热议股票
{"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"REGN","data":{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":773.94,"timestamp":1767128400000,"preClose":780.5,"halted":0,"volume":383197,"hourTrading":{"tag":"盘后","latestPrice":775,"preClose":773.94,"latestTime":"17:43 EST","volume":21223,"amount":16425867.684200002,"timestamp":1767134616438},"delay":0,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"盘后交易","change":-6.56,"latestTime":"12-30 18:25:46 EST","open":776.3,"high":777.77,"low":770.3,"amount":296346128.0243,"amplitude":0.009571,"askPrice":775.5,"askSize":34,"bidPrice":773.35,"bidSize":50,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1767142800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":780.5,"dividendRate":0.004548,"preHourTrading":{"tag":"盘前","latestPrice":780.58,"preClose":780.5,"latestTime":"09:28 EST","volume":93,"amount":72382.086,"timestamp":1767104885753},"postHourTrading":{"tag":"盘后","latestPrice":775,"preClose":773.94,"latestTime":"17:43 EST","volume":21223,"amount":16425867.684200002,"timestamp":1767134616438},"volumeRatio":0.688361,"impliedVol":0.3519,"impliedVolPercentile":0.32},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.496032915481120","cardData":[{"tweetId":"496032915481120","author":{"authorId":"3551780874549647","idStr":"3551780874549647","name":"瞪羚侃新股","avatar":"https://static.tigerbbs.com/3c51d12626fd16c5502d8d7a95cad382","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.14","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"fanSize":587,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"Biotech和大药企全新合作方式，诞生","digest":"谁说Biotech让大药企掏钱必须卖自家管线？一种很新的Biotech和大药企之间的交易合作方式已经出现。 10月30日，药明巨诺与再生元Regeneron签署战略合作补充协议：再生元为药明巨诺的MAGE-A4靶点产品相关特定开发活动提供资金，再生元获得药明巨诺自研的药品生产工艺的全球非独家许可，并获得药明巨诺自研的慢病毒载体制造工艺的选择权，药明巨诺将获得最高可达5000万美金的付款，涵盖首付款、产品开发里程碑付款、药品生产流程监管里程碑付款等一系列款项。 值得注意的是，此次涉及的MAGE-A4靶点产品（JWTCR001）是一款TCR-T疗法，由药明巨诺2022年下半年从2seventy bio（后续被再生元收购）引进，此次合作药明巨诺仍保留了大中华区开发及商业化该产品的权益，它并非是一次管线回收的交易。 尽管JWTCR001是引进的管线，但过往中国Biotech的交易历史来看，从未有过在同一个资产下引进方技术反哺授权方并获得技术授权付款的先河，药明巨诺和再生元这一创新式合作补充显然有很多价值挖掘点。 01 创新交易先河 从国内Biotech过往合作交易历史上，与海外药企达成合作无非几种，包括买卖管线权益、技术平台使用授权、药物特许权折现。 药明巨诺与再生元的合作并不完全属于上述任何一种，该合作款项由“产品开发款项+技术授权费用+选择权费用”组成，一是“再生元为药明巨诺特定开发活动提供资金”和存在产品里程碑开发付款，这更像是一种再生元资助和推动药明巨诺在国内开发这款引进管线，毕竟从药明巨诺自身的管线优先级来说这款管线并不算靠前；二是药明巨诺将自研的生产工艺非独家授权给再生元以及再加一个慢病毒载体制造工艺的技术授权选择权，过往国内Biotech大多数技术授权集中在新型分子发现的技术平台使用权，而这种药品和载体生产工艺授权是CGT Biotech独有的，在过往的交易合作中并不","plainDigest":"谁说Biotech让大药企掏钱必须卖自家管线？一种很新的Biotech和大药企之间的交易合作方式已经出现。 10月30日，药明巨诺与再生元Regeneron签署战略合作补充协议：再生元为药明巨诺的MAGE-A4靶点产品相关特定开发活动提供资金，再生元获得药明巨诺自研的药品生产工艺的全球非独家许可，并获得药明巨诺自研的慢病毒载体制造工艺的选择权，药明巨诺将获得最高可达5000万美金的付款，涵盖首付款、产品开发里程碑付款、药品生产流程监管里程碑付款等一系列款项。 值得注意的是，此次涉及的MAGE-A4靶点产品（JWTCR001）是一款TCR-T疗法，由药明巨诺2022年下半年从2seventy bio（后续被再生元收购）引进，此次合作药明巨诺仍保留了大中华区开发及商业化该产品的权益，它并非是一次管线回收的交易。 尽管JWTCR001是引进的管线，但过往中国Biotech的交易历史来看，从未有过在同一个资产下引进方技术反哺授权方并获得技术授权付款的先河，药明巨诺和再生元这一创新式合作补充显然有很多价值挖掘点。 01 创新交易先河 从国内Biotech过往合作交易历史上，与海外药企达成合作无非几种，包括买卖管线权益、技术平台使用授权、药物特许权折现。 药明巨诺与再生元的合作并不完全属于上述任何一种，该合作款项由“产品开发款项+技术授权费用+选择权费用”组成，一是“再生元为药明巨诺特定开发活动提供资金”和存在产品里程碑开发付款，这更像是一种再生元资助和推动药明巨诺在国内开发这款引进管线，毕竟从药明巨诺自身的管线优先级来说这款管线并不算靠前；二是药明巨诺将自研的生产工艺非独家授权给再生元以及再加一个慢病毒载体制造工艺的技术授权选择权，过往国内Biotech大多数技术授权集中在新型分子发现的技术平台使用权，而这种药品和载体生产工艺授权是CGT Biotech独有的，在过往的交易合作中并不","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1762132334638,"gmtModify":1762136375454,"symbols":["LEGN","02126","REGN"],"themeIds":["c49795052d464d13b35de2ee5aacb221"],"themes":[{"themeId":"c49795052d464d13b35de2ee5aacb221","themeType":0,"name":"【复盘】静候最强11月！大家10月投资如何？"}],"popularizeThemeFlag":false,"imageCount":2,"images":[{"url":"https://static.tigerbbs.com/eb4bbcbd69f00e3df0492db1e99241af","width":"640","height":"306"}],"repostCount":0,"viewCount":2425,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/496032915481120","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7168,"displayRows":2,"foldSize":0,"authorId":"3551780874549647"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.485332629250304","cardData":[{"tweetId":"485332629250304","author":{"authorId":"3495752422317040","idStr":"3495752422317040","name":"寂寞一根烟.","avatar":"https://static.tigerbbs.com/b9971fed0c28a4b06e1b594a3fb63b53","userType":1,"introduction":"","crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/REGN\">$再生元制药公司(REGN)$ </a> 这么垃圾的么，就你跳水最凶","plainDigest":"$再生元制药公司(REGN)$ 这么垃圾的么，就你跳水最凶","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1759518186344,"gmtModify":1759536503950,"symbols":["REGN"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":877,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/485332629250304","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":47,"displayRows":2,"foldSize":0,"authorId":"3495752422317040"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.484688051929176","cardData":[{"tweetId":"484688051929176","author":{"authorId":"4144751444625622","idStr":"4144751444625622","name":"Pan the man","avatar":"https://community-static.tradeup.com/news/2fd53ef58442bc6a50658efeefc5e413","userType":1,"introduction":"","crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":106,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"药价政策新格局下的投资机会：为什么REGN值得关注？ 近期，美国医药政策迎来重大变化。特朗普政府宣布对进口药品征收高额关税，并要求药企在美国市场实施“最惠国定价”。辉瑞（Pfizer, PFE）率先达成协议，以降价换取三年关税豁免，并通过新平台“TrumpRx”直销药品。这一政策转变意味着：未来药企必须在美国市场面对更严格的价格管控，但能与政府达成协议的公司有望获得先发优势。 在这一背景下，生物制药龙头<a href=\"https://ttm.financial/S/REGN\">$再生元制药公司(REGN)$</a> 值得重点关注。 为什么选择REGN？ 1. 核心产品竞争力强 REGN的明星产品 Eylea（眼科药物） 在全球市场占据领先地位，即使在降价压力下，凭借其高临床价值和医生依赖度，需求仍具粘性。未来，Eylea高清剂量版（HD）有望进一步稳固市场地位。 2. 抗体研发平台优势 REGN长期深耕单克隆抗体技术，在免疫学和肿瘤学管线中积累大量潜在“爆款”药物。与政府谈判时，拥有多管线研发优势的公司，往往更容易通过差异化药物议价。 3. 与政府合作潜力 辉瑞的案例表明，率先与政府达成协议的药企能获得显著的市场回报。REGN在新冠疫情期间曾与政府深度合作研发抗体疗法，未来若进入TrumpRx平台，其与医保体系的绑定可能带来新的稳定现金流。 4. 财务稳健 REGN现金流强劲，资产负债率低，即使面临药价下调压力，也能保持研发投入，抵御行业波动。 相关概念股推荐 在特朗普新政和药品降价趋势下，以下几只股票同样具备布局价值： •<a href=\"https://ttm.financial/S/AMGN\">$安进(AMGN)$ </a> 作为美国老牌生物制药巨头，Amgen产品组合涵盖肿瘤、自身免疫及罕见病领域，产品线广泛。其长期分红与稳定增长属性，使其在","plainDigest":"药价政策新格局下的投资机会：为什么REGN值得关注？ 近期，美国医药政策迎来重大变化。特朗普政府宣布对进口药品征收高额关税，并要求药企在美国市场实施“最惠国定价”。辉瑞（Pfizer, PFE）率先达成协议，以降价换取三年关税豁免，并通过新平台“TrumpRx”直销药品。这一政策转变意味着：未来药企必须在美国市场面对更严格的价格管控，但能与政府达成协议的公司有望获得先发优势。 在这一背景下，生物制药龙头$再生元制药公司(REGN)$ 值得重点关注。 为什么选择REGN？ 1. 核心产品竞争力强 REGN的明星产品 Eylea（眼科药物） 在全球市场占据领先地位，即使在降价压力下，凭借其高临床价值和医生依赖度，需求仍具粘性。未来，Eylea高清剂量版（HD）有望进一步稳固市场地位。 2. 抗体研发平台优势 REGN长期深耕单克隆抗体技术，在免疫学和肿瘤学管线中积累大量潜在“爆款”药物。与政府谈判时，拥有多管线研发优势的公司，往往更容易通过差异化药物议价。 3. 与政府合作潜力 辉瑞的案例表明，率先与政府达成协议的药企能获得显著的市场回报。REGN在新冠疫情期间曾与政府深度合作研发抗体疗法，未来若进入TrumpRx平台，其与医保体系的绑定可能带来新的稳定现金流。 4. 财务稳健 REGN现金流强劲，资产负债率低，即使面临药价下调压力，也能保持研发投入，抵御行业波动。 相关概念股推荐 在特朗普新政和药品降价趋势下，以下几只股票同样具备布局价值： •$安进(AMGN)$ 作为美国老牌生物制药巨头，Amgen产品组合涵盖肿瘤、自身免疫及罕见病领域，产品线广泛。其长期分红与稳定增长属性，使其在","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1759362681113,"gmtModify":1759363374961,"symbols":["LLY","MRNA","AMGN","VRTX","REGN"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":1857,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/484688051929176","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1999,"displayRows":2,"foldSize":0,"authorId":"4144751444625622"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.467845648842952","cardData":[{"tweetId":"467845648842952","author":{"authorId":"3502767768442965","idStr":"3502767768442965","name":"话题虎","avatar":"https://static.tigerbbs.com/d418c2def5dc1d094b03270b450f71ce","userType":4,"introduction":"热点追踪小能手，为大家捕捉每日最热市场话题","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":37732,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【晒单有奖】终于跟上了巴菲特的步伐！快来晒晒你的UNH~","digest":"喜欢抄底的小虎们，大家有福了呀[可爱]一个芯片 <a href=\"https://laohu8.com/S/INTC\">$英特尔(INTC)$</a> ，一个医疗 <a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$</a> ，一个保险 <a href=\"https://laohu8.com/S/UNH\">$联合健康(UNH)$</a> ，都涨得不错，这段时间大科技把其他板块流动性都抽干了，是该拣点便宜货了[得意]而且这一次，是有各个大佬的助阵的。最新13F数据，截止2025年 Q2，“大空头”Michael Burry本轮重点押注医疗板块，eg. 建仓了UNH、 <a href=\"https://laohu8.com/S/REGN\">$再生元制药公司(REGN)$</a> 的长期看涨期权（Leap Call）和正股，合计超37%的仓位，对这个赛道接下来近一年都很乐观；David Tepper也在Q2加仓了7亿美元的UNH，减仓了拼多多、阿里巴巴等Q1重仓的中概；另外能把UNH股价盘后拉升10%的，主要还是巴菲特，他真的买了！伯克希尔·哈撒韦Q2买了15亿美元，超500万股的UNH，季末市值约16亿美元，另外加仓了 <a href=\"https://laohu8.com/S/NUE\">$纽柯钢铁(NUE)$</a> , <a href=\"https://laohu8.com/S/LEN\">$莱纳建筑公司(LEN)$</a> , <a href=\"https://laohu8.com/S/POOL\">$Pool Corporation(POOL)$</a> , <a href=\"https://laohu8.com/S/DHI\">$霍顿房屋(DHI)$</a> ，继续减持","plainDigest":"喜欢抄底的小虎们，大家有福了呀[可爱]一个芯片 $英特尔(INTC)$ ，一个医疗 $礼来(LLY)$ ，一个保险 $联合健康(UNH)$ ，都涨得不错，这段时间大科技把其他板块流动性都抽干了，是该拣点便宜货了[得意]而且这一次，是有各个大佬的助阵的。最新13F数据，截止2025年 Q2，“大空头”Michael Burry本轮重点押注医疗板块，eg. 建仓了UNH、 $再生元制药公司(REGN)$ 的长期看涨期权（Leap Call）和正股，合计超37%的仓位，对这个赛道接下来近一年都很乐观；David Tepper也在Q2加仓了7亿美元的UNH，减仓了拼多多、阿里巴巴等Q1重仓的中概；另外能把UNH股价盘后拉升10%的，主要还是巴菲特，他真的买了！伯克希尔·哈撒韦Q2买了15亿美元，超500万股的UNH，季末市值约16亿美元，另外加仓了 $纽柯钢铁(NUE)$ , $莱纳建筑公司(LEN)$ , $Pool Corporation(POOL)$ , $霍顿房屋(DHI)$ ，继续减持","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1755242498257,"gmtModify":1755242542068,"symbols":["INTC","AAPL","LEN","DHI","LLY","NUE","POOL","REGN","UNH"],"themeIds":["24ff14a7adea45e3884d3654afc80911"],"themes":[{"themeId":"24ff14a7adea45e3884d3654afc80911","themeType":0,"name":"UNH绩后冲高回落！接下来看涨or看跌？"}],"popularizeThemeFlag":false,"imageCount":3,"images":[{"url":"https://static.tigerbbs.com/c296b899ff62804cc9a7ca08bd8fc607"},{"url":"https://static.tigerbbs.com/b0bebabfe48c98923c9a7c653f7f6a1b"},{"url":"https://static.tigerbbs.com/70a3bbcba04f6fda98a30fb209a96094"}],"repostCount":2,"viewCount":15090,"likeCount":4,"liked":false,"collected":false,"commentCount":7,"hotComments":[{"id":"467867188498448","author":{"authorId":"5400656025182","idStr":"5400656025182","name":"vision","avatar":"https://static.tigerbbs.com/d67e47e5bb77491f2c37ae81c5386950","userType":1,"introduction":"","userGiftHeadFrame":"https://static.tigerbbs.com/2dbc245fdbd9b115beaa630c8980fb6f","crmLevel":7,"crmLevelSwitch":0,"fanSize":15630,"starInvestorFlag":false},"content":"$联合健康(UNH)$申请出战","plainContent":"$联合健康(UNH)$申请出战","likeCount":0,"commentType":"hot","coins":50},{"id":"467923106140656","author":{"authorId":"4087422624240810","idStr":"4087422624240810","name":"AliceSam","avatar":"https://static.tigerbbs.com/77ff717dd7a06de56315c65060829a03","userType":1,"introduction":"","crmLevel":12,"crmLevelSwitch":0,"fanSize":4274,"starInvestorFlag":true,"starInvestorFollowerNum":170},"content":"一个芯片 $英特尔(INTC)$ ，一个医疗 $礼来(LLY)$ ，一个保险 $联合健康(UNH)$ ，都涨得不错 [开心][开心][开心]","plainContent":"一个芯片 $英特尔(INTC)$ ，一个医疗 $礼来(LLY)$ ，一个保险 $联合健康(UNH)$ ，都涨得不错 [开心][开心][开心]","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":true,"reward":{"totalAmount":1000},"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/467845648842952","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":1237,"displayRows":2,"foldSize":0,"authorId":"3502767768442965"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.462734683791664","cardData":[{"tweetId":"462734683791664","author":{"authorId":"4182503943177972","idStr":"4182503943177972","name":"27RR","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":50,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/REGN\">$REGN(REGN)$</a> 各位系好安全带，明早盘前将发布财报","plainDigest":"$REGN(REGN)$ 各位系好安全带，明早盘前将发布财报","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1753978237300,"gmtModify":1753978248653,"symbols":["REGN"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/9ca5bb567c4795c02c19d914d66ea896","width":"1170","height":"2522"}],"repostCount":0,"viewCount":772,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/462734683791664","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":45,"displayRows":2,"foldSize":0,"authorId":"4182503943177972"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.452039385153920","cardData":[{"tweetId":"452039385153920","author":{"authorId":"3576724815704857","idStr":"3576724815704857","name":"去会所","avatar":"https://static.tigerbbs.com/de401c0bd93eac5813aa71ee994e439c","userType":1,"introduction":"","crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/REGN\">$再生元制药公司(REGN)$ </a> 还有两天，能涨30%？救救我的期权[流泪] ","plainDigest":"$再生元制药公司(REGN)$ 还有两天，能涨30%？救救我的期权[流泪]","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1751387164498,"gmtModify":1751387165570,"symbols":["REGN"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":774,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/452039385153920","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":57,"displayRows":2,"foldSize":0,"authorId":"3576724815704857"}],"position":0}],"size":6,"extra":{"requestId":"b587dc10ff3c4a81960076097798f3b2","feedVerCode":"2"}},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20434302","market":"us","labels":[],"media":"sec.gov","original_id":"AN100027525000166-REGN","pdf_url":"","pub_time":1763614800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"REGN","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000100027525000166/0001000275-25-000166-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000100027525000166/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEFMam29iM8jM9oWuC","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-20 13:00","pubTimestamp":1763614800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20385339","market":"us","labels":[],"media":"sec.gov","original_id":"AN196922325000926-REGN","pdf_url":"","pub_time":1762491600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"REGN","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000196922325000926/0001969223-25-000926-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000196922325000926/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEHtup6YN18FfkwdtE","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-11-07 13:00","pubTimestamp":1762491600,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20337941","market":"us","labels":[],"media":"sec.gov","original_id":"AN195824425004419-REGN","pdf_url":"","pub_time":1761710400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"REGN","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000195824425004419/0001958244-25-004419-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000195824425004419/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE35vMEVzVpBA89dJP","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2025-10-29 12:00","pubTimestamp":1761710400,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20320310","market":"us","labels":[],"media":"sec.gov","original_id":"AN87258925000028-REGN","pdf_url":"","pub_time":1761624000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"REGN","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-20250930.htm","primary":true,"translateUrl":"","linkName":"regn-20250930.htm","type":"10-Q","id":"NTFILEFiVdQo4QgVSwcYhf","market":"us","size":2285515},{"description":"CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-ex_311x09302025x10q.htm","primary":false,"translateUrl":"","linkName":"regn-ex_311x09302025x10q.htm","type":"EX-31.1","id":"NTFILE8jEL2UQqDnNVnt6E","market":"us","size":11829},{"description":"CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-ex_312x09302025x10q.htm","primary":false,"translateUrl":"","linkName":"regn-ex_312x09302025x10q.htm","type":"EX-31.2","id":"NTFILE5bWJCkCqwVcL1uau","market":"us","size":11898},{"description":"CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C SECTION 1350","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-ex_32x09302025.htm","primary":false,"translateUrl":"","linkName":"regn-ex_32x09302025.htm","type":"EX-32","id":"NTFILE2MSnietZdA5obVX4","market":"us","size":6762}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-10-28 12:00","pubTimestamp":1761624000,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20320067","market":"us","labels":[],"media":"sec.gov","original_id":"AN87258925000026-REGN","pdf_url":"","pub_time":1761624000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/0000872589-25-000026-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm","primary":true,"translateUrl":"","linkName":"exhibit991q32025.htm","type":"EX-99.1","id":"NTFILECtLTh5mU8tvv4uyH","market":"us","size":471588},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/regn-20251028.htm","primary":false,"translateUrl":"","linkName":"regn-20251028.htm","type":"8-K","id":"NTFILEGWPYatznJx2nATY8","market":"us","size":24225},{"description":"","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/image0a12.jpg","primary":false,"translateUrl":"","linkName":"image0a12.jpg","type":"GRAPHIC","id":"NTFILEBnLDnEeFVoLZKano","market":"us","size":7835}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-10-28 12:00","pubTimestamp":1761624000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20241263","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925096921-REGN","pdf_url":"","pub_time":1759723200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/0001104659-25-096921-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FORM 8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/tm2528010d1_8k.htm","primary":true,"translateUrl":"","linkName":"tm2528010d1_8k.htm","type":"8-K","id":"NTFILE88nukoB7KA4DRo7t","market":"us","size":28856}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-10-06 12:00","pubTimestamp":1759723200,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition","summary_zh":"项目2.02：经营业绩和财务状况","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19937303","market":"us","labels":[],"media":"sec.gov","original_id":"AN87258925000019-REGN","pdf_url":"","pub_time":1754020800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"REGN","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/0000872589-25-000019-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-20250630.htm","primary":true,"translateUrl":"","linkName":"regn-20250630.htm","type":"10-Q","id":"NTFILE6aj3pgtnyEdLieF3","market":"us","size":2162902},{"description":"AMENDED AND RESTATED CERTIFICATE OF INCORPORATION","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-ex_31x06302025.htm","primary":false,"translateUrl":"","linkName":"regn-ex_31x06302025.htm","type":"EX-3.1","id":"NTFILE4R5oLF62D1o484Wn","market":"us","size":98799},{"description":"AMENDED AND RESTATED COLLAB. AGREEMENT BY AND BETWEEN THE REGISTRANT AND SANOFI","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-ex_101x06302025.htm","primary":false,"translateUrl":"","linkName":"regn-ex_101x06302025.htm","type":"EX-10.1","id":"NTFILE4MtXwAT7xuJj3Acu","market":"us","size":41066},{"description":"CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-ex_311x06302025x10q.htm","primary":false,"translateUrl":"","linkName":"regn-ex_311x06302025x10q.htm","type":"EX-31.1","id":"NTFILE3S4EQstCowZjYoxt","market":"us","size":11827},{"description":"CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-ex_312x06302025x10q.htm","primary":false,"translateUrl":"","linkName":"regn-ex_312x06302025x10q.htm","type":"EX-31.2","id":"NTFILE2oqdcfN5UhjyfMLv","market":"us","size":11896},{"description":"CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C SECTION 1350","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-ex_32x06302025.htm","primary":false,"translateUrl":"","linkName":"regn-ex_32x06302025.htm","type":"EX-32","id":"NTFILEEDJX3oneK6VCsx9M","market":"us","size":6753}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-08-01 12:00","pubTimestamp":1754020800,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19937288","market":"us","labels":[],"media":"sec.gov","original_id":"AN87258925000017-REGN","pdf_url":"","pub_time":1754020800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/0000872589-25-000017-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm","primary":true,"translateUrl":"","linkName":"exhibit991q22025.htm","type":"EX-99.1","id":"NTFILEC7TpY3HFxSwpA2X8","market":"us","size":461148},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/regn-20250801.htm","primary":false,"translateUrl":"","linkName":"regn-20250801.htm","type":"8-K","id":"NTFILEBn21AT9Biy295Wsu","market":"us","size":23459},{"description":"","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/image0a12a.jpg","primary":false,"translateUrl":"","linkName":"image0a12a.jpg","type":"GRAPHIC","id":"NTFILEC2dvaZRtypV9T3Jx","market":"us","size":7835}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-08-01 12:00","pubTimestamp":1754020800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19785916","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925060637-REGN","pdf_url":"","pub_time":1750219200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465925060637/0001104659-25-060637-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 5.07: Submission of Matters to a Vote of Security Holders","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"FORM 8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925060637/tm2518262d1_8k.htm","primary":true,"translateUrl":"","linkName":"tm2518262d1_8k.htm","type":"8-K","id":"NTFILE5W3VHrvpUtX2GX3V","market":"us","size":41014}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-06-18 12:00","pubTimestamp":1750219200,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.07: Submission of Matters to a Vote of Security Holders","summary_zh":"项目5.07：将事项提交证券持有人表决","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19568326","market":"us","labels":[],"media":"sec.gov","original_id":"AN180422025000022-REGN","pdf_url":"","pub_time":1745899200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"REGN","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/0001804220-25-000022-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm","primary":true,"translateUrl":"","linkName":"regn-20250331.htm","type":"10-Q","id":"NTFILE5mqyyFMbPV2vNvRS","market":"us","size":1722803},{"description":"CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-ex_311x03312025x10q.htm","primary":false,"translateUrl":"","linkName":"regn-ex_311x03312025x10q.htm","type":"EX-31.1","id":"NTFILEFsHzaZkCs9KpJ6gE","market":"us","size":12002},{"description":"CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-ex_312x03312025x10q.htm","primary":false,"translateUrl":"","linkName":"regn-ex_312x03312025x10q.htm","type":"EX-31.2","id":"NTFILE9HEPbQGzV2D5Xpsp","market":"us","size":12071},{"description":"CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C SECTION 1350","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-ex_32x03312025.htm","primary":false,"translateUrl":"","linkName":"regn-ex_32x03312025.htm","type":"EX-32","id":"NTFILE5njLPCa9WdvxtWqJ","market":"us","size":6864}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-04-29 12:00","pubTimestamp":1745899200,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19567561","market":"us","labels":[],"media":"sec.gov","original_id":"AN180422025000020-REGN","pdf_url":"","pub_time":1745899200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/0001804220-25-000020-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm","primary":true,"translateUrl":"","linkName":"exhibit991q12025.htm","type":"EX-99.1","id":"NTFILE6mQQS6qYZZrz2Kih","market":"us","size":345939},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/regn-20250429.htm","primary":false,"translateUrl":"","linkName":"regn-20250429.htm","type":"8-K","id":"NTFILEDBUQd6yoSk7c8wTe","market":"us","size":23764},{"description":"null","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/image0a12.jpg","primary":false,"translateUrl":"","linkName":"image0a12.jpg","type":"GRAPHIC","id":"NTFILEAPEk3bBNBcdmD44d","market":"us","size":7835}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-04-29 12:00","pubTimestamp":1745899200,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19848355","market":"us","labels":[],"media":"sec.gov","original_id":"AN180422025000014-REGN","pdf_url":"","pub_time":1743711805000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"REGN","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/0001804220-25-000014-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000014/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILE76HNxs3E72Rwo1F1","market":"us","size":13520},{"description":"GRAPHIC","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000014/a69201485641ama03.jpg","primary":false,"translateUrl":"","linkName":"a69201485641ama03.jpg","type":"GRAPHIC","id":"NTFILEC8wTXCHabUzvQUHe","market":"us","size":7021}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2025-04-04 04:23","pubTimestamp":1743711805,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19146500","market":"us","labels":[],"media":"sec.gov","original_id":"AN180422025000011-REGN","pdf_url":"","pub_time":1738731600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","symbol":"REGN","title":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","titleType":"年度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","us_notice_code":"Form 10-K","us_title_en":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm","primary":true,"translateUrl":"","linkName":"regn-20241231.htm","type":"10-K","id":"NTFILEBm2479Y4QfKRkGX8","market":"us","size":3189208},{"description":"DESCRIPTION OF SECURITIES","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_41x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_41x12312024x10k.htm","type":"EX-4.1","id":"NTFILE5mYayPo71SGhhp3g","market":"us","size":16140},{"description":"AMENDMENT AGREEMENT, DATED DECEMBER 30, 2014 BETWEEN BAYER AND REGISTRANT","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_1081x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_1081x12312024x10k.htm","type":"EX-10.8 1","id":"NTFILECsCyRd3PL45gTW4D","market":"us","size":136841},{"description":"INSIDER TRADING POLICY","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_191x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_191x12312024x10k.htm","type":"EX-19.1","id":"NTFILE7Zyf5ZuwucyPRkCY","market":"us","size":83542},{"description":"SUBSIDIARIES OF THE REGISTRANT","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_211x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_211x12312024x10k.htm","type":"EX-21.1","id":"NTFILE8ajLcVWHSAK6wPoM","market":"us","size":22167},{"description":"CONSENT OF PRICEWATERHOUSECOOPERS LLP","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_231x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_231x12312024x10k.htm","type":"EX-23.1","id":"NTFILE7ZUpqWyo3TrnDuBR","market":"us","size":2640},{"description":"CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_311x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_311x12312024x10k.htm","type":"EX-31.1","id":"NTFILEZB4XDrMUiin28KF3","market":"us","size":12001},{"description":"CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_312x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_312x12312024x10k.htm","type":"EX-31.2","id":"NTFILECWSbFmgvZMm8Vwh5","market":"us","size":12048},{"description":"CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-ex_32x12312024x10k.htm","primary":false,"translateUrl":"","linkName":"regn-ex_32x12312024x10k.htm","type":"EX-32","id":"NTFILE5Mc8kBCRPW2xRupp","market":"us","size":6838},{"description":"","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/image_0a.jpg","primary":false,"translateUrl":"","linkName":"image_0a.jpg","type":"GRAPHIC","id":"NTFILE7BSZygqqSm9LQMKM","market":"us","size":10123},{"description":"","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231_g1.jpg","primary":false,"translateUrl":"","linkName":"regn-20241231_g1.jpg","type":"GRAPHIC","id":"NTFILEHWj793dNnUS5XnZU","market":"us","size":110340}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"年度报告","pubTime":"2025-02-05 13:00","pubTimestamp":1738731600,"title_zh":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19142778","market":"us","labels":[],"media":"sec.gov","original_id":"AN180422025000007-REGN","pdf_url":"","pub_time":1738645200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/0001804220-25-000007-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm","primary":true,"translateUrl":"","linkName":"exhibit991q42024.htm","type":"EX-99.1","id":"NTFILECfZ8JbEP74egKXH4","market":"us","size":542703},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/regn-20250204.htm","primary":false,"translateUrl":"","linkName":"regn-20250204.htm","type":"8-K","id":"NTFILECcdK1DJ4iqtfMmHA","market":"us","size":27878},{"description":"","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/image0a12.jpg","primary":false,"translateUrl":"","linkName":"image0a12.jpg","type":"GRAPHIC","id":"NTFILE5uv9T4PabYjGHtpx","market":"us","size":7835}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-02-04 13:00","pubTimestamp":1738645200,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目2.02：经营业绩和财务状况；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19037613","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925002826-REGN","pdf_url":"","pub_time":1736744400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"REGN","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/0001104659-25-002826-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EXHIBIT 99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm","primary":true,"translateUrl":"","linkName":"tm253014d1_ex99-1.htm","type":"EX-99.1","id":"NTFILEG6LoKa1vdBXy6RMP","market":"us","size":102227},{"description":"FORM 8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_8k.htm","primary":false,"translateUrl":"","linkName":"tm253014d1_8k.htm","type":"8-K","id":"NTFILEJ3s7TcJf1d8NwW88","market":"us","size":33923},{"description":"EXHIBIT 99.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2.htm","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2.htm","type":"EX-99.2","id":"NTFILEF4NChLv5gKgKEoq5","market":"us","size":79925},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1img1.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-1img1.jpg","type":"GRAPHIC","id":"NTFILEHZUp7w6PzQSsstUh","market":"us","size":4059},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img01.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img01.jpg","type":"GRAPHIC","id":"NTFILE8fqWcSZZSWwzNhPj","market":"us","size":113531},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img02.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img02.jpg","type":"GRAPHIC","id":"NTFILE6eD7HfM5xu9xKXQR","market":"us","size":118694},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img03.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img03.jpg","type":"GRAPHIC","id":"NTFILE5Yg4tf6azRyD7irU","market":"us","size":471265},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img04.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img04.jpg","type":"GRAPHIC","id":"NTFILE5driDTEW4KtwQGKQ","market":"us","size":207154},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img05.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img05.jpg","type":"GRAPHIC","id":"NTFILE3NURLsbJGfjp7PUe","market":"us","size":229013},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img06.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img06.jpg","type":"GRAPHIC","id":"NTFILE7nxuseR9hRcEX3BH","market":"us","size":170593},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img07.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img07.jpg","type":"GRAPHIC","id":"NTFILE3XEzaH1ZgkS9567C","market":"us","size":184440},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img08.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img08.jpg","type":"GRAPHIC","id":"NTFILE3uKE81kLn8jQ8Hct","market":"us","size":164775},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img09.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img09.jpg","type":"GRAPHIC","id":"NTFILE7KZ6U1igm2rewb8E","market":"us","size":240000},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img10.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img10.jpg","type":"GRAPHIC","id":"NTFILE5ebESzMrtZtPwbja","market":"us","size":227307},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img11.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img11.jpg","type":"GRAPHIC","id":"NTFILE2GEfYcybDpjk5cEA","market":"us","size":284967},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img12.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img12.jpg","type":"GRAPHIC","id":"NTFILE4UiMMFkUzLLftjAS","market":"us","size":119340},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img13.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img13.jpg","type":"GRAPHIC","id":"NTFILEAm8YdBdhUzgebLsm","market":"us","size":264084},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img14.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img14.jpg","type":"GRAPHIC","id":"NTFILEvzQFgetes6rSkR1J","market":"us","size":222169},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img15.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img15.jpg","type":"GRAPHIC","id":"NTFILEEdPbKtCFAjrGB1vB","market":"us","size":250981},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img16.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img16.jpg","type":"GRAPHIC","id":"NTFILE7yqhRREC4bCyvxqg","market":"us","size":243983},{"description":"GRAPHIC","seq":24,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img17.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img17.jpg","type":"GRAPHIC","id":"NTFILEBPY6amwBcEiDpmrS","market":"us","size":250774},{"description":"GRAPHIC","seq":25,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img18.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img18.jpg","type":"GRAPHIC","id":"NTFILEBfdhmwrGq7KRKrSb","market":"us","size":289400},{"description":"GRAPHIC","seq":26,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img19.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img19.jpg","type":"GRAPHIC","id":"NTFILECHNv1eTyM414nWoG","market":"us","size":294411},{"description":"GRAPHIC","seq":27,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img20.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img20.jpg","type":"GRAPHIC","id":"NTFILE7W4oiiiWfDn41kmu","market":"us","size":231184},{"description":"GRAPHIC","seq":28,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img21.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img21.jpg","type":"GRAPHIC","id":"NTFILEFi7dS4bDNjwYkeXj","market":"us","size":190736},{"description":"GRAPHIC","seq":29,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img22.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img22.jpg","type":"GRAPHIC","id":"NTFILE9u1dkW8pA3EhwALy","market":"us","size":263484},{"description":"GRAPHIC","seq":30,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img23.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img23.jpg","type":"GRAPHIC","id":"NTFILEF7MxwJzHPjaUuxWx","market":"us","size":228074},{"description":"GRAPHIC","seq":31,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img24.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img24.jpg","type":"GRAPHIC","id":"NTFILEAM3Y8bLkbdwnkDFX","market":"us","size":277809},{"description":"GRAPHIC","seq":32,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img25.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img25.jpg","type":"GRAPHIC","id":"NTFILED6NhFcqFkCwLjdFR","market":"us","size":261253},{"description":"GRAPHIC","seq":33,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img26.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img26.jpg","type":"GRAPHIC","id":"NTFILE2Vz12knTZ3u3h8Ki","market":"us","size":256207},{"description":"GRAPHIC","seq":34,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img27.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img27.jpg","type":"GRAPHIC","id":"NTFILEAtLidNoYQeqCi3FZ","market":"us","size":261880},{"description":"GRAPHIC","seq":35,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img28.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img28.jpg","type":"GRAPHIC","id":"NTFILE5ba7dzubVXa8V9BF","market":"us","size":253934},{"description":"GRAPHIC","seq":36,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img29.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img29.jpg","type":"GRAPHIC","id":"NTFILE2AaNX8SXjw6MSiAv","market":"us","size":254276},{"description":"GRAPHIC","seq":37,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img30.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img30.jpg","type":"GRAPHIC","id":"NTFILEHnArpnnMUys15bfG","market":"us","size":236746},{"description":"GRAPHIC","seq":38,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img31.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img31.jpg","type":"GRAPHIC","id":"NTFILE3zDKZX6CXYWw6ZV3","market":"us","size":225621},{"description":"GRAPHIC","seq":39,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img32.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img32.jpg","type":"GRAPHIC","id":"NTFILEBF3MKEHhXJj3onU7","market":"us","size":264900},{"description":"GRAPHIC","seq":40,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img33.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img33.jpg","type":"GRAPHIC","id":"NTFILE27UAjBFVWYH5kefJ","market":"us","size":211513},{"description":"GRAPHIC","seq":41,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img34.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img34.jpg","type":"GRAPHIC","id":"NTFILE4oEtSaTvqKQym23f","market":"us","size":248074},{"description":"GRAPHIC","seq":42,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img35.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img35.jpg","type":"GRAPHIC","id":"NTFILECbh4LZ9zAS1jVqQq","market":"us","size":268371},{"description":"GRAPHIC","seq":43,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img36.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img36.jpg","type":"GRAPHIC","id":"NTFILE7LtjJfjyuaEvKtTT","market":"us","size":265401},{"description":"GRAPHIC","seq":44,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img37.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img37.jpg","type":"GRAPHIC","id":"NTFILE6dknZjqq2j52aqpp","market":"us","size":162197},{"description":"GRAPHIC","seq":45,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img38.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img38.jpg","type":"GRAPHIC","id":"NTFILEBbr4WRUsDZfkM2M4","market":"us","size":234736},{"description":"GRAPHIC","seq":46,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img39.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img39.jpg","type":"GRAPHIC","id":"NTFILEGhwXdNDpovnxwVuB","market":"us","size":108137},{"description":"GRAPHIC","seq":47,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img40.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img40.jpg","type":"GRAPHIC","id":"NTFILE6c2Zm3dUKLxH8oBh","market":"us","size":228758},{"description":"GRAPHIC","seq":48,"linkUrl":"https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-2img41.jpg","primary":false,"translateUrl":"","linkName":"tm253014d1_ex99-2img41.jpg","type":"GRAPHIC","id":"NTFILE9jvnaoLAvejpjm4U","market":"us","size":265869}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-01-13 13:00","pubTimestamp":1736744400,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0015},{"period":"1month","weight":0.0004},{"period":"3month","weight":0.3881},{"period":"6month","weight":0.4249},{"period":"1year","weight":0.0956},{"period":"ytd","weight":0.0957}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0065},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1086},{"period":"1year","weight":0.156},{"period":"ytd","weight":0.1736}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.03899},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.514286,"avgChangeRate":0.044119}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"aProfile":null}}}